infection. These results will be forwarded as soon as they are 
available. 
IV. Activation of human peripheral blood lymphocytes in the 
presence of antiviral agents and lack of effect on retroviral 
transduction. 
In order to transduce human peripheral blood lymphocytes 
with retroviral vectors and avoid activation of latent HIV, we 
have utilized conditions which are selectively cytotoxic for HIV. 
This strategy employs the use of non-nucleoside reverse 
transcriptase inhibitors which eliminate HIV in vitro but do not 
affect murine retroviral gene reverse transcription. These 
agents include B-HAP-E and CD4 pseudomonas exotoxin (Upjohn, 
Inc., Kalamazoo, MI) or niverapine (Boehringer Mannheim, Inc.). 
As previously published (21) , incubation of these cells under 
these conditions prevents the activation of HIV. At the same 
time, no effects are seen on transduction using a retroviral 
vector encoding ^-galactosidase (BAG) in the presence of these 
agents. Thus, these conditions will be used in the transfection 
protocol to introduce the recombinant genes into seropositive 
patients with HIV infection without activating latent virus. 
[38] 
Recombinant DNA Research, Volume 18 
